Blog
RSS FeedPosted by Michael Wonder on 31 Oct 2023
Basic health insurance to cover test that can predict return of breast cancer
30 October 2023 - A special test that predicts the chance of hormone-sensitive breast cancer returning will be added to ...
Posted by Michael Wonder on 10 Oct 2023
Patient access to medicines for rare health conditions at sustainable costs can be strengthened
2 October 2023 - The Swedish Dental and Medicines Benefits Agency, TLV, today submits a report to the government on how ...
Posted by Michael Wonder on 02 Apr 2023
Survey on patients' access to medicines for the treatment of rare health conditions
31 March 2023 - The TLV has submitted an interim report to the government for the task of proposing how ...
Posted by Michael Wonder on 28 Mar 2023
Clarification on the subsidy limitation for drugs for diabetes
28 March 2023 - The TLV has clarified the subsidy limitation for all GLP-1 receptor agonists. ...
Posted by Michael Wonder on 21 Nov 2022
TLV subsidises anti-viral treatment of COVID-19 to risk groups
21 November 2022 - Paxlovid, which treats patients who are at risk of becoming seriously ill from COVID-19, will be ...
Posted by Michael Wonder on 21 Nov 2022
TLV subsidises drugs against cystic fibrosis
18 November 2022 - The Dental and Pharmaceutical Benefits Agency, TLV, has decided that the drugs Kaftrio, Kalydeco and Symkevi, ...
Posted by Michael Wonder on 08 Jun 2022
TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast ...
Posted by Michael Wonder on 02 Jun 2022
TLV reconsiders subsidy of the IL-17 and IL-23 inhibitors
2 June 2022 - The TLV has started a trial for the interleukin 17 and interleukin 23 inhibitors. ...
Posted by Michael Wonder on 16 May 2022
Tepmetko is granted a temporary subsidy
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
Posted by Michael Wonder on 08 Sep 2021
Withdrawals from pharmaceutical benefits on 1 October 2021
8 September 2021 - Suboxone is among the medicines that will be withdrawn from the drug benefits at the companies' ...
Posted by Michael Wonder on 11 Aug 2021
Withdrawals from the pharmaceutical benefits on 1 September 2021
10 August 2021 - Faslodex is among the medicines being withdrawn from the drug benefits on 1 September 2021. ...
Posted by Michael Wonder on 03 May 2021
TLV reconsiders subsidy for eleven TNF alfa inhibitors included in the high-cost protection
30 April 2021 - Today, eleven subcutaneous TNF-alpha inhibitors are included in the high-cost protection. ...
Posted by Michael Wonder on 18 Dec 2020
Medicines for hepatitis C remain in the high-cost protection after TLV's reconsideration
18 December 2020 - During the autumn, the Swedish Dental and Pharmaceutical Benefits Agency, TLV, reconsidered the subsidy of the hepatitis ...
Posted by Michael Wonder on 24 Oct 2020
New cancer treatment with the precision drug Vitrakvi is included in the high-cost protection
23 October 2020 - For the first time in Sweden, a cancer drug against a specific genetic change, instead of against ...
Posted by Michael Wonder on 30 Sep 2020
Saxenda is not included in the high-cost protection
29 September 2020 - Liraglutide (Saxenda), which is intended for weight control in adult patients with obesity or are overweight, ...